8-K: Neurocrine Biosciences Restructures Takeda Collaboration, Gains Global Rights to Osavampator Excluding Japan

Neurocrine Biosciences amends its agreement with Takeda, securing exclusive worldwide rights to develop and commercialize osavampator, a potential treatment for major depressive disorder, excluding Japan.

Summary

• Neurocrine Biosciences has amended its exclusive license agreement with Takeda Pharmaceutical Company Limited regarding osavampator.
• The revised agreement grants Neurocrine exclusive global rights to develop and commercialize osavampator for all indications, except in Japan, where Takeda regains exclusive rights.
• Osavampator is a potential first-in-class AMPA positive allosteric modulator being developed for patients with inadequate response to major depressive disorder (MDD) treatment.
• Under the new terms, each company will bear development costs in their respective territories and receive royalty payments based on the other party's net sales.
• Neurocrine plans to initiate a Phase 3 program for osavampator in the first half of this year, following a successful End-of-Phase 2 meeting with the FDA.
• Neurocrine expects tiered royalties payable to Takeda to be in the mid-to-upper teens in the United States and low double-digits outside of the United States on a blended basis as percentage of net sales.
• Neurocrine would be entitled to receive royalties from Takeda on net sales in Japan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Neurocrine gains more control over a key asset, but also takes on more risk and responsibility. The Phase 3 plans are encouraging, but the reliance on royalties and potential regulatory hurdles temper the optimism.

Positives

• Neurocrine gains greater control over the development and commercialization of osavampator in most global markets.
• The streamlined collaboration allows Neurocrine to focus on bringing osavampator to patients more quickly.
• The company plans to initiate a Phase 3 program for osavampator in the first half of this year.
• Takeda's expertise in neuroscience is acknowledged, potentially validating the drug's prospects.
• Neurocrine would be entitled to receive royalties from Takeda on net sales in Japan.

Negatives

• Neurocrine relinquishes rights to osavampator in the Japanese market.
• Neurocrine will be responsible for all development costs outside of Japan.
• Neurocrine will need to pay royalties to Takeda on net sales of osavampator.

Risks

• Clinical development activities may be delayed or unsuccessful.
• The FDA or other regulatory authorities may make adverse decisions regarding osavampator.
• The potential benefits of the agreement with Takeda may not be realized.
• Osavampator may be precluded from commercialization by the proprietary or regulatory rights of third parties.
• Osavampator may have unintended side effects, adverse reactions, or incidents of misuse.

Future Outlook

Neurocrine Biosciences plans to initiate a Phase 3 program for osavampator in the first half of this year and anticipates potential royalty revenues from Takeda's sales in Japan, while paying royalties to Takeda on sales outside of Japan.

Management Comments

• 'This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible,' said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences.
• 'With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.'
• 'As it continues to progress through clinical development, osavampator has the potential to add a meaningful new treatment option for patients with MDD,' said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda.

Industry Context

This announcement reflects a trend in the pharmaceutical industry towards strategic collaborations and licensing agreements to share development costs and commercialization risks, particularly in complex therapeutic areas like neuroscience. Companies like Neurocrine often partner with larger firms like Takeda to leverage their expertise and resources in specific geographic regions or therapeutic areas.

Comparison to Industry Standards

• Licensing agreements in the pharmaceutical industry commonly involve royalty rates in the range of single to double digits, depending on the stage of development, market potential, and exclusivity.
• Neurocrine's expected royalty payments to Takeda in the mid-to-upper teens in the United States and low double-digits outside of the United States are within the typical range for a Phase 3 asset.
• Similar deals, such as the collaboration between AbbVie and Voyager Therapeutics for gene therapies, also involve upfront payments, milestone payments, and tiered royalties.
• The return of rights to Takeda for the Japanese market is not uncommon, as companies often focus on regions where they have established infrastructure and expertise.

Stakeholder Impact

• Shareholders may react positively to Neurocrine gaining greater control over osavampator.
• Patients with MDD may benefit from a potential new treatment option.
• Takeda will continue to benefit from the collaboration through royalty payments and rights in Japan.

Next Steps

• Neurocrine will file the Restated License Agreement with the SEC as an exhibit to its Quarterly Report on Form 10-Q for the period ending March 31, 2025.
• Neurocrine plans to initiate a Phase 3 program for osavampator in the first half of this year.

Key Dates